These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 6145766)
1. The metabolism of dopamine, NN-dialkylated dopamines and derivatives of the dopamine agonist 2-amino-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) by catechol-O-methyltransferase. Youde IR; Raxworthy MJ; Gulliver PA; Dijkstra D; Horn AS J Pharm Pharmacol; 1984 May; 36(5):309-13. PubMed ID: 6145766 [TBL] [Abstract][Full Text] [Related]
2. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN. Rollema H; Westerink BH; Mulder TB; Dijkstra D; Feenstra MG; Horn AS Eur J Pharmacol; 1980 Jun; 64(4):313-23. PubMed ID: 7389825 [TBL] [Abstract][Full Text] [Related]
3. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and alpha-substituted catecholamines. Gordonsmith RH; Raxworthy MJ; Gulliver PA Biochem Pharmacol; 1982 Feb; 31(3):433-7. PubMed ID: 6803810 [TBL] [Abstract][Full Text] [Related]
4. Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase. Rivett AJ; Roth JA Biochemistry; 1982 Apr; 21(8):1740-2. PubMed ID: 7082642 [TBL] [Abstract][Full Text] [Related]
5. Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin. Wikström H; Elebring T; Hallnemo G; Andersson B; Svensson K; Carlsson A; Rollema H J Med Chem; 1988 Jun; 31(6):1080-4. PubMed ID: 2967374 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of catechol-O-methyltransferase by 6,7-dihydroxy-3,4-dihydroisoquinolines related to dopamine: demonstration using liquid chromatography and a novel substrate for O-methylation. Cheng BY; Origitano TC; Collins MA J Neurochem; 1987 Mar; 48(3):779-86. PubMed ID: 2433397 [TBL] [Abstract][Full Text] [Related]
7. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Lotta T; Vidgren J; Tilgmann C; Ulmanen I; Melén K; Julkunen I; Taskinen J Biochemistry; 1995 Apr; 34(13):4202-10. PubMed ID: 7703232 [TBL] [Abstract][Full Text] [Related]
8. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Meyer MR; Maurer HH Chem Res Toxicol; 2009 Jun; 22(6):1205-11. PubMed ID: 19462939 [TBL] [Abstract][Full Text] [Related]
9. O-methylation of (+)-(R)- and (-)-(S)-6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in the presence of pig brain catechol-O-methyltransferase. Hötzl BK; Thomas H Chirality; 1997; 9(4):367-72. PubMed ID: 9275315 [TBL] [Abstract][Full Text] [Related]
11. 2-hydroxyethynyloestradiol as a substrate for catechol-O-methyltransferase--implications in the metabolism of ethynyloestradiol. Raxworthy MJ; Gulliver PA J Steroid Biochem; 1982 Jul; 17(1):17-21. PubMed ID: 7109588 [TBL] [Abstract][Full Text] [Related]
12. O-methylation of dopamine-o-sulfates with catechol-0-methyltransferase. Qu YQ; Imai K; Tamura Z; Hashimoto Y; Miyazaki H Life Sci; 1983 Apr; 32(16):1811-8. PubMed ID: 6835012 [TBL] [Abstract][Full Text] [Related]
13. Effects of ADTN and various other 2-aminotetralin derivatives on the efflux of 3H-dopamine from rat striatal slices. Mulder AH; Braakhuis B; De Regt V; Dijkstra D; Horn AS Eur J Pharmacol; 1980 Jun; 64(4):349-55. PubMed ID: 7389827 [TBL] [Abstract][Full Text] [Related]
14. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively. Urwyler S; Markstein R J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868 [TBL] [Abstract][Full Text] [Related]
15. Enzymatic O-methylation of the dopamine agonist dipropyl-5,6-dihydroxyaminotetralin: isolation and structure elucidation of the O-methylated metabolite. Rollema H; Grol CJ Pharm Weekbl Sci; 1983 Aug; 5(4):159-64. PubMed ID: 6622210 [TBL] [Abstract][Full Text] [Related]
16. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism. Brannan T; Prikhojan A; Yahr MD J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195 [TBL] [Abstract][Full Text] [Related]
17. Dihydroxynitrobenzaldehydes and hydroxymethoxynitrobenzaldehydes: synthesis and biological activity as catechol-O-methyltransferase inhibitors. Pérez RA; Fernández-Alvarez E; Nieto O; Piedrafita FJ J Med Chem; 1992 Nov; 35(24):4584-8. PubMed ID: 1469689 [TBL] [Abstract][Full Text] [Related]
18. Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Raxworthy MJ; Youde IR; Gulliver PA Xenobiotica; 1986 Jan; 16(1):47-52. PubMed ID: 2868577 [TBL] [Abstract][Full Text] [Related]
19. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127 [TBL] [Abstract][Full Text] [Related]
20. Catechol O-methyltransferase activity in the human placenta and liver. Burba JV Can J Physiol Pharmacol; 1979 Feb; 57(2):213-6. PubMed ID: 546488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]